Youngil Koh

Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study

Seok Jin Kim, Jing Quan Lim, Yurike Laurensia et al. · Blood · 2020 · 124 citations · Full text

Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI

Qaid Ahmed Shagera, Gi Jeong Cheon, Youngil Koh et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2019 · 74 citations

Positron Emission Tomography, Lymphoid Neoplasia, Metabolic Tumour Volume +8

Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia

Sang Eun Yoon, Yuqin Song, Seok Jin Kim et al. · The Lancet Regional Health - Western Pacific · 2021 · 57 citations · Full text

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results

Shinya Rai, Won Seog Kim, Kiyoshi Ando et al. · Haematologica · 2022 · 51 citations · Full text

Phase Iib Results, Hematological Malignancy, Lymphoid Neoplasia +15

Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

Yuqin Song, Luis Malpica, Qingqing Cai et al. · The Lancet Oncology · 2023 · 43 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8